CCR5 antagonists (maraviroc, leronlimab) and CXCR4 antagonists (balixafortide, burixafor, GMI-1359, motixafortide) have also been shown to synergistically inhibit tumor development in combination with chemotherapy [114–119]. This evidence concerns the gene CCR5 and neoplasm.